These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21870199)

  • 1. Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.
    Li Y; Zhang J; He D; Liang Q; Wang Y
    J Mol Model; 2012 May; 18(5):1907-16. PubMed ID: 21870199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.
    Bian X; Dong W; Zhao Y; Sun R; Kong W; Li Y
    J Mol Model; 2014 Apr; 20(4):2166. PubMed ID: 24633771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Dynamics Simulations to Investigate the Binding Mode of the Natural Product Liphagal with Phosphoinositide 3-Kinase α.
    Gao Y; Ma Y; Yang G; Li Y
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27367663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors.
    Freitas de Sousa FJ; Nunes Azevedo FF; Santos de Oliveira FL; Vieira Carletti J; Freire VN; Zanatta G
    J Biomol Struct Dyn; 2024 Nov; 42(18):9283-9293. PubMed ID: 37632299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity.
    Wang J; Wang F; Xiao Z; Sheng G; Li Y; Wang Y
    J Mol Model; 2012 Jul; 18(7):2943-58. PubMed ID: 22139479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach.
    Gadhe CG; Kothandan G; Cho SJ
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1636-44. PubMed ID: 23796247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monte Carlo loop refinement and virtual screening of the thyroid-stimulating hormone receptor transmembrane domain.
    Ali MR; Latif R; Davies TF; Mezei M
    J Biomol Struct Dyn; 2015; 33(5):1140-52. PubMed ID: 25012978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel potential PI3Kα inhibitors for cancer therapy.
    Zhang Q; Sang F; Qian J; Lyu S; Wang W; Wang Y; Li Q; Du L
    J Biomol Struct Dyn; 2021 Jul; 39(10):3721-3732. PubMed ID: 32425109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
    Zhou H; Wang C; Ye J; Chen H; Tao R
    Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
    Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
    Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.
    Han M; Zhang JZ
    J Chem Inf Model; 2010 Jan; 50(1):136-45. PubMed ID: 19928754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor.
    Talekar M; Kendall J; Denny W; Jamieson S; Garg S
    Eur J Pharm Sci; 2012 Dec; 47(5):824-33. PubMed ID: 23069617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoin Schiff Bases: Design, Synthesis, and Biological Evaluation as Potential Antitumor Agents.
    Sabbah DA; Al-Tarawneh F; Talib WH; Sweidan K; Bardaweel SK; Al-Shalabi E; Zhong HA; Abu Sheikha G; Abu Khalaf R; Mubarak MS
    Med Chem; 2018; 14(7):695-708. PubMed ID: 29651943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
    Meher BR; Wang Y
    J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.